LuciAfa — Afatinib 40 mg, 30 pcs, Lucius

LuciAfa — Afatinib Tablets 40 mg, 30 Tablets

Product code: 495

8940₴ 9745₴ -8% On order · from 10 days

Analogues

Afanat LuciAfa
1
Active ingredient
Dosage form Tablets
Tablets per pack 30

LuciAfa is a potent second-generation targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is afatinib at a strength of 40 mg supplied as film-coated oral tablets (Afatinib Tablets 40 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Afatinib is an irreversible, selective pan-HER inhibitor that blocks signaling not only from the epidermal growth factor receptor (EGFR / HER1) but also from other members of the HER family (HER2 / ErbB2 and HER4 / ErbB4), while effectively suppressing HER receptor heterodimerization. Through irreversible covalent binding to the receptor kinase domain, afatinib overcomes resistance to first-generation inhibitors (gefitinib, erlotinib) caused by resistance mutations (such as T790M) and demonstrates high efficacy against uncommon activating EGFR mutations (exon 19 deletions, exon 21 L858R substitutions, and exon 20 mutations).

Supplied in a package containing 30 tablets of 40 mg (a full 1-month treatment course). Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAfa 40 mg:

  • ✅ Irreversible Pan-HER Inhibition: Blocks EGFR (HER1), HER2, and HER4, providing deeper and more sustained suppression of tumor growth.
  • ✅ Overcoming Resistance: High activity against specific activating EGFR mutations and certain first-generation resistance mutations.
  • ✅ Proven Clinical Efficacy: Significant prolongation of progression-free survival in EGFR-mutated non-small cell lung cancer.
  • ✅ Convenient Dosing Regimen: Taken orally once daily on an empty stomach.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Gilotrif / Giotrif).

LuciAfa is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Afatinib (as afatinib dimaleate) — 40 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate. Coating: hypromellose, macrogol, titanium dioxide, colorants.

Packaging and Presentation: Film-coated tablets, 40 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciAfa (Afatinib Tablets 40 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Afatinib is an irreversible blocker of the ErbB receptor family. It covalently binds to the kinase domains of EGFR (HER1), HER2, and HER4, resulting in irreversible termination of kinase signaling across these receptors. This leads to tumor cell proliferation inhibition and apoptosis in cell lines harboring HER receptor amplification or mutations.

Pharmacokinetics:

  • Absorption: Following oral administration, peak plasma concentrations (Tmax) are achieved within 2 to 5 hours. Concomitant administration with a high-fat meal significantly reduces systemic exposure (must always be taken strictly on an empty stomach!).
  • Distribution: Human plasma protein binding is approximately 95%.
  • Metabolism: Low hepatic metabolism via enzymatic pathways; primary metabolic reactions involve covalent protein binding.
  • Elimination: Excreted predominantly via feces (85.4% of dose) and renally (4.3%). Terminal elimination half-life (T1/2) averages approximately 37 hours.

LuciAfa is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations as detected by a validated test (as monotherapy in first-line settings or following prior chemotherapy).

LuciAfa is administered orally once daily every day.

Dosing Regimen:
The recommended standard daily dose is 40 mg once daily.

Administration Guidelines:
Tablets must be taken on an empty stomach — at least 1 hour before or 3 hours after a meal. Swallow tablets whole with water; do not break, crush, or dissolve. If a dose is missed, take it on the same day as soon as remembered (however, if less than 8 hours remain before the next scheduled dose, skip the missed dose).

Administration of LuciAfa is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to afatinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Evaluated drug interactions with afatinib include:

  • P-glycoprotein (P-gp) Inhibitors (ritonavir, cyclosporine, ketoconazole, erythromycin): May elevate afatinib plasma concentrations. If co-administration is necessary, P-gp inhibitors should be administered simultaneously with or after afatinib.
  • P-glycoprotein (P-gp) Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Can significantly decrease afatinib blood exposure and reduce antitumor efficacy (avoid concurrent use).
  • Gastric pH-Altering Agents: Antacids do not significantly affect afatinib absorption when proper dosing intervals are observed.

Pregnancy:
LuciAfa is contraindicated during pregnancy. Based on its mechanism of action, afatinib may cause teratogenic and embryotoxic harm. Females of reproductive potential must utilize effective, reliable contraception during treatment and for at least 2 weeks following the final dose.

Lactation:
Excretion of afatinib into human breast milk has been demonstrated in preclinical studies. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract (Very Common): Diarrhea (principal dose-limiting adverse effect requiring prompt antidiarrheal therapy such as loperamide and adequate hydration), stomatitis, nausea, vomiting, decreased appetite.
  • Dermatologic Reactions (Very Common): Rash/acne, dermatitis, dry skin, pruritus, paronychia (nail bed inflammation).
  • General Disorders: Fatigue, weight loss, epistaxis (nosebleeds).
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), hypokalemia.

Symptoms:
Symptoms of afatinib overdose include exacerbation of typical adverse reactions: rash, stomatitis, diarrhea, nausea, vomiting, fatigue, headache, and elevated bilirubin levels.

Treatment:
No specific antidote exists. In case of overdose, discontinue therapy and initiate supportive and symptomatic care.

Storage Requirements for LuciAfa 40 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAfa 40 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Afatinib Tablets 40 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00